Drug Profile


Alternative Names: WCK-2349

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wockhardt
  • Class Antibacterials; Antifungals; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • Phase II Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 30 Jun 2017 Phase-III clinical trials in Skin and soft tissue infections in India (PO) (CTRI/2017/06/008843)
  • 02 Jan 2017 Chemical structure information added
  • 09 Apr 2016 Final adverse events and pharmacokinetics data from a phase I trial in volunteers with hepatic impairment presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases Session (ECCMD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top